Allos Therapeutics, Inc. leads Tuesday small-cap pre-market volume
Allos Therapeutics, Inc. (Nasdaq: ALTH) reported its clinical trial for Efaproxyn failed to show that the drug improved survival in women with breast cancer that spread to the brain.
EPIX Pharmaceuticals, Inc. (Nasdaq: EPIX) announced that it has received a negative response from the FDA regarding the company's appeal for immediate approval of Vasovist, a treatment used to diagnose vascular disease.
Syntax-Brillian Corp. (Nasdaq: BRLC) is launching its new 65” LCD high-definition television today.
Vical Inc. (Nasdaq: VICL) reported that preliminary late-stage trial results showed a drug candidate successfully treated the blood flow disease ischemia by increasing the size of blood vessels.
Analyst William Ho raised his rating on Acorda Therapeutics Inc. (Nasdaq: ACOR) to “buy” from “neutral.”
The following are the most actively traded companies in Tuesday pre-market trading among those with market capitalizations under $500 million:
| Price at | % | ||||||
| 9:16 et | Change | Change | Volume | Year High | Year Low |
